Predictive Medicine
The German Federation of Diabetics believes that it is meaningful for people, living under the risk of suffering from a specific disease, to evaluate the risk factors more precisely by means of Predictive Medicine. On the other hand it might be ethically questionable to apply those methods in cases, in which serious consequences (e.g. death) can possibly be expected. For the patients this could be a situation of extraordinary mental stress. In those cases predictive methods or tests should only be applied, if a patient has given an explicit mandate. In our opinion results of such methods of testing should only be communicated to the patient by qualified medical specialists. However, when we are talking about disease patterns, in which a patient's behaviour, in combination with a qualified therapy, could avoid a worsening of the disease, the chances of Predictive Medicine should be employed.
Prevention
Prevention is not only a problem in our public healthcare system but also a problem of our society in general. Despite the fact that every third teenager carries the risk of diabetes there is almost no effort in prevention. This is even worse as genetic, family-related and socio-economic factors play a critical role in the further growing up of the adolescent persons. Hence prevention and working towards a healthy lifestyle should already start on the pre-school level, for example in the kindergarten or play school. The steadily increasing number of children and adolescents suffering from diabetes type 2 is significant. Normally information about the disease diabetes and a healthy lifestyle does not start before the manifestation of the disease took place. Especially for those patients, carrying a high risk, special risk-related measures of prevention should regularly be taken.
Personalised Medicine
The German Federation of Diabetics expects considerable success when Personalised Medicine is applied in the treatment of serious and/or chronic diseases. In Germany the influence of economic factors on political decisions on health care has been growing. The legislative organs and self-governing bodies impose strict regulations on doctors and therapists, which in most cases only allow standardised treatment. However, from our point of view individual treatment by means of biomarkers provides a lot of advantages:
& Insufficient or even wrong treatment and therapies could be avoided & Risks or adverse reactions of pharmaceuticals and therapies could be avoided or limited & With individual treatment from the beginning, unnecessary cost for insufficient or wrong treatment could be eliminated & Patients could be protected from significant complications of the disease and also from cost.
The rising incidence of diabetes, metabolic syndrome, and subsequent vascular diseases is a major public health problem in industrialized countries. Diabetes is a progressive disease with a complex pathophysiology that includes peripheral insulin resistance, declining β-cell function and mass, declining insulin secretion over time, inappropriate glucagon secretion and hepatic glucose production, and deficiencies in amylin and glucagon-like peptide (GLP-1).
The main pharmacological drugs that have been used in the treatment of type 2 diabetes are: α-glucosidase inhibitors, to delay intestinal carbohydrate absorption (e. g. acarbose); biguanides to target hepatic insulin resistance (e.g. metformin); insulin secretagogues or sulphonylureas, to increase pancreatic insulin secretion and also increase glucose-induced insulin secretion (e.g. glibenclamide; gliclazide); insulin sensitisers or thiazolidinediones, to target adipocyte and muscle insulin resistance (e.g. troglitazone; rosiglitazone); and intestinal lipase inhibitors, to inhibit fat absorption and promote weight loss in obese patients (e.g. orlistat) (Figure) .
Observational studies have found that bariatric surgery is effective in patients with obesity and diabetes, reinstating near normal glycaemia in 50-80% of patients for several years. Bariatric surgery is now an accepted treatment for obese patients with diabetes. The finding that glycaemic control is promptly reinstated in most patients with diabetes when less food passes through the stomach, duodenum, and proximal jejunum-independently of the amount of weight lost-has focused attention on research into gastrointestinal factors as a potential source of new drugs for the treatment of type 2 diabetes. Several gastrointestinal peptides (including GLP-1, glucose dependent insulinotrophic polypeptide, and peptide YY) could provide a basis for new treatments in patients with obesity and diabetes. DPP-4 inhibitors and GLP-1 agonists stimulate glucosemediated insulin secretion from pancreatic β cells and suppress glucagon release; GLP-1 agonists also delay gastric emptying; and amylin agonists suppress glucagon release and delay gastric emptying. Combination therapy that includes drugs with complementary mechanisms of action is most effective and sometimes preferred. There is great potential for developing a new generation of therapeutics that offer better control of diabetes, its co-morbidities and its complications. This contribution summarizes current pharmacological approaches to treat diabetes mellitus and will focus on novel therapies for diabetes mellitus that are under development. Potential new treatments include analogues of intestinal and adipocyte hormones, inhibitors of renal glucose reabsorption and cellular glucocorticoid activation, and activators of cellular energy production.
The world-wide epidemic of obesity has fueled the increasing incidence of type 2 diabetes mellitus. In turn, type 2 diabetes is associated with major target organ complications with increased morbidity and mortality. Indeed, nephropathy is a prominent complication of type 2 diabetes with end-stage renal failure which requires renal dialysis and/or renal transplantation. It is, therefore, imperative to identify novel diagnostic predictors for early detection, and monitoring progression, of target organ pathologies such as nephropathy. A hallmark feature of type 2 diabetes mellitus is hyperglycemia-induced oxidative stress and consequent DNA damage. Thus, identification of indices of DNA injury that co-relate with disease progression and manifestation of target organ pathologies are urgently needed. While the modified nucleoside, 8-hydroxydeoxyguanosine (8-OHdG), is a useful index of oxidative DNA damage, γH2AX has emerged has a sensitive index of double-strand DNA (dsDNA) breaks, the most severe form of DNA injury. Accordingly, the focus of our recent studies was to examine the impact of insulin resistance/type 2 diabetes mellitus on urinary and/or renal tissue 8-OHdG and γH2AX utilizing two highly relevant animal models of the disease, namely the obese Zucker rat (OZR) and db/db mouse (and their respective lean nondiabetic controls, LZR and db/ m, respectively); these animal models lack the leptin receptor and thus are markedly obese, insulin resistant and hyperglycemic. The OZR displayed mild hyperglycemia but marked hyperinsulinemia in association with increased albuminuria compared to the lean controls. The aim of the first one is to discourage proliferations, and second-to prevent and relieve the contraction of the fibroproliferative vitreoretinal membranes (Fig. 1 ).
Laser photocoagulation (LFK)-retinal burns is still the "golden standard" in prevention and treatment of PDR. Destruction of the new vessels required burns involve the full thickness retina and often lead to nerve fiber field defects. Although being treated with LFK, some of the patients develop severe complications and underwent surgical procedure. Recovery of good vision after surgery in PDR in the early vitrectomy group is observed only in 24.5% of the patients. The prevalence of DM in type 2 diabetes after 5 years duration is about 5% compared to 20% after 20 years of duration.
The classification of DM is: diabetic macular edema (DME), ischaemic maculopathy and vitreomacular interface changes. Improving the diagnostic techniques, a lot of ongoing studies have investigated different medications for intravitreal usage in conditions of DME (Fig. 2) . The grid LFK on the leaking microaneurisams in combination with focal LFK is still one of the important treatments of DME. Up to date medications include the corticosteroids and Anti-VEGF drugs. A lot of studies such as READ (Resolve, Restore and DRCR.net Study Group) have summarised the latest results. Improvement in findings does not always match to visual acuity increase. The treatment of the vitreomacular interface changes is surgical, but without great improvement, and the changes are recurrent. There is no effective treatment for ischemic macular changes, which are always associated with severe visual loss. Despite a lot of investigations run, there is still no any protocol elaborated for DME treatment.
Considering the fact that about 26% of patients with type 1 and 36% type 2 diabetic patients have never had their eyes examined, the risk for different ocular complications is very high: 32% of patients with diabetes at high-risk for visual loss never undergo an eye examination. When examined almost 61% of these patients are found to have diabetic retinopathy, cataract, glaucoma or other ocular pathologies.
In order to prevent the ocular diabetic complications, healthcare and eye-care delivery system on a personalbased level should be enhanced in societies. The only key to success: focusing on "individuals" but not on "patients" with already manifested disorders to apply innovative investigation approaches in the general population and groups at risk.
ANKLE-BRACHIAL INDEX IN TYPE 2 DIABETES PATIENTS AND CARDIOVASCULAR RISK
Nussbaumerova B, Rosolova H, Sefrna F, Sipova I, Sifalda P 2nd Medical Department, Charles University in PragueMedical Faculty in Pilsen, Czech Republic
Purpose: The ankle-brachial index (ABI), i.e. the ratio of systolic blood pressure (SBP) measured on the ankle and on the arm, is considered the diagnostic parameter for the Results: The ABI<0.9 was found unilateral in 20 DM2 (8 %), bilateral in 27 (11%), thus the ABI was decreased in 47 (19%) DM2. Other 168 DM2 (66%) showed the normal ABI and 38 (15%) the nondiagnostic ABI. There was no significant difference in the characteristics of DM2 patients with the normal and the nondiagnostic ABI. The DM2 patients with the ABI≤0.9 compared to the rest of the sample were older males with elevated total cholesterol, total homocystein and CAC and with the history of CV diseases. Many CV and metabolic risk factors correlated significantly positively with ABI<0.9: age, glycaemia, total homocystein, CAC (p<0.05), LDL-cholesterol (p<0.01) and SBP (p<0.01). The ABI<0.9 was significantly and independently associated with age (p<0.001), smoking (p<0.01), LDL-cholesterol, total homocystein and CAC (p<0.05). The decreased ABI was a strong significant predictor of ischemic stroke and symptomatic carotid stenosis for the next 3 years (p<0.001). The ABI<0.9 correlated significantly neither with ultrasensitive C-reactive protein nor with presence of the metabolic syndrome in DM2. Conclusion: Decreased ABI<0.9 was found in 19% of DM2 patients. It was in a significant and independent association with age, smoking, LDL-cholesterol, total homocystein and CAC. We evaluated ABI<0.9 as a strong predictor of ischemic stroke and symptomatic carotid artery stenosis. That is why these patients need an individual, complex and intensive intervention. Nondiagnostic ABI values were found in 15% of the sample; a high prevalence of mediocalcinosis in DM2 patients is suspected. Immune cell functions such as adherence, chemotaxis and phagocytosis, and monocytes/macrophage cell line that is hyper-responsive to bacterial antigens resulting in increased production of pro-inflammatory cytokines IL-1β and TNF-α. Periodontitis is accompanied by gingival bleeding and the production of an inflammatory exudate termed gingival crevicular fluid (GCF) that arises from the inflamed gingival tissues surrounding the teeth. GCF contains byproducts of connective tissue degradation, enzymes from host and bacterial cells, cytokines and other inflammatory mediators, and has been studied for screening blood glucose and for biomarkers of both diabetes and periodontitis. Studies conducted to date suggest that gingival crevicular fluid may be an acceptable substitute for "finger stick" blood for determination of serum glucose levels and may therefore be a useful screening tool in the dental office. Although the ideal immuneinflammatory biomarker is yet to be found, some of the promising cytokines expressed in the GCF that are elevated in both periodontitis and diabetes include IL-1β, IL-6, PGE 2 , and VEGF. Further research is necessary to clarify the usefulness of these potential biomarkers and to likewise investigate additional cytokines which have to be studied in this regard.
ENDOTHELIAL DYSFUNCTION IN DIABETES: POTENTIAL APPLICATION OF CIRCULATING MARKERS AS ADV ANCED DIAGNOSTIC AND PROGNOSTIC TOOLS
Abebe W, Mozaffari MS Department of Oral Biology, College of Dental Medicine, Georgia Health Sciences University, Augusta, Georgia, USA Diabetes mellitus is a common chronic metabolic disease with a growing prevalence rate worldwide. It is associated with vascular disorders, which contribute to as high as 80% of the 3.2 million annual deaths attributed to complications of diabetes. Endothelial dysfunction plays a crucial and an initiating role in vascular disorders in both type 1 and type 2 diabetes and insulin resistance/prediabetes. In the majority of diabetic cases, it precedes the development of overt hyperglycemia and its consequent complications. Assessing the status of the endothelium can serve as a valuable early diagnostic and prognostic tool for vascular diseases in diabetes. In human subjects, endothelial function/dysfunction has been evaluated using several in vivo techniques based on the measurement of the functional consequences of endothelial activity (i.e., relaxation/lumen size alterations in blood vessels). The commonly utilized techniques in this 
Cancer-related mortality in diabetics
According to the current worldwide statistics, every 10 seconds one patient dies on Diabetes mellitus (DM) related consequences. Once appeared, cancer outcomes have worse prognosis for diabetics compared to non-diabetic oncologic patients ( Figure 1 ). The overall concept of cancer-predisposition in diabetics
Diabetics may be highly predisposed to cancer development specifically due to following contributors:
-strong stress factors (excessive metabolic alterations, disturbed glucose/insulin homeostasis, hormonal deregulation, insufficient detoxification) with consequently excessive production of ROS. -mitochondrial dysfunction with consequent low energy production, insufficient repair capacity and accumulating damage to both chromosomal and mitochondrial DNA. -high risk for infectious disorders with consequently induced viral proto-oncogenic activity as well as activity of particular pathogenic bacterial forms such as Helicobacter pylori.
Adequacy of stress response, repair capacity as well as immune defence are highly individual for each patient and strongly depend on risk factors such as genetic background, age, environmental factors, nutrition, body culture, life style, etc.
Outlook
Current biotechnology possesses sufficient power to estimate a severity of damage to sub-cellular structures, individual stress reactions and repair capacity. For example, by stress proteome profiling in peripheral leukocytes and blood plasma, individual stress reactions can be well estimated. Advanced predictive diagnostic approaches are currently close to clinical application and allow to select groups of risk and to estimate a predisposition to severe complications in diabetics. Much attention should be focused on targeted preventive arrangements in diabetes care, in order to restrict or even avoid severe secondary complications, such as cancer.
BARIATRIC MEDICINE: MULTIDISCIPLINARY APPROACH FOR OBESITY PREVENTION
Dimitrov DV Medical University Varna, Varna, Bulgaria
Obesity and its associated diseases are epidemic that represent a major threat to human health. In the last two decades an explosive increase in the number of people diagnosed with diabetes has been observed worldwide and the global figure of affected individuals is expected to rise from currently 250 million to 350 million in 2025. The rapidly escalating number of affected patients at even very young age poses a tremendous burden on the public health system and a substantial reinforcement of research activities including transnational cooperation between scientists from different disciplines is urgently required to avoid a socioeconomic disaster. Dietary interventions and pharmacological strategies, however, failed to deliver success, due to side effects (e.g. sibutramine, rimonabant) or lack of efficacy (e.g. lorcaserin, recombinant leptin). For patients with obesity and type 2 diabetes, bariatric surgery is by far the most effective treatment-it is, indeed, the only form of treatment that can put patients into full long-term remission. This contribution reviews rise and fall of anti-obesity treatments and highlights the importance of bariatric surgery as the only way to cut diabetes costs at present. We discuss also public health implications. Until a successful non-surgical means for preventing and reversing obesity is developed, bariatric surgery appears to be the only intervention that can result in a sustained reversal of both obesity and type 2 diabetes mellitus in most patients receiving it. One of the key recommendations is the need for a multidisciplinary bariatric team to oversee the ongoing needs of patients after surgery, as well as to build a weight maintenance program. Beside surgeon, such bariatric medicine team should include metabolic physicians, nutritionists, physical activities specialists, cardiologists, etc. Background: The metabolic syndrome (MS) is a cluster of metabolic abnormalities, such as abdominal obesity, arterial hypertension, and atherogenic dyslipidaemia, which are associated with development of secondary complications such as type 2 diabetes (DM2). Recently, many studies showed pathology-specific polymorphisms in apolipoprotein genes that might be associated with the development of DM2. Objective: To study a possible association of several polymorphisms of apo-genes APOA1 G-75A, APOA1 C83T, APOC3 Sst1, APOE epsilon, APOA5 T-1131C, and APOA5 S19W with DM2 in MS patients.
MSCS AS TOOLS FOR RESTORING
Study population: MS patients with DM2, including 100 males and 264 females, average age 50.9±0.5, and controls, including 114 healthy males (average age 40.0±0.5) and 84 females (average age 85.9±0.5). All of them were examined clinically, biochemically and genetically. Results: Among male MS patients with DM2, there was a higher rate of carries of APOE e2-allele compared to the controls (22% vs. 13%, p=0.067). In addition, male patients demonstrated a higher rate of carries of APOA5 19W-allele compared to the controls (13% vs. 3%, p= 0.005). There was not a significant difference in genotype distribution of the studied apo-genes between female groups. All studied groups were shown to correspond to Hardy-Weinberg equilibrium. Conclusion: Gender (male) is considered as a risk factor in a diseases progression. Our results suggest that the APOE and APOA5 S19W polymorphisms are of significance in male patients with DM2. 
ASSOCIATION OF ACE I AND FABP2 GENES

